Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder
- 6 December 2011
- journal article
- case report
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 18 (1), 113-115
- https://doi.org/10.1177/1352458511431973
Abstract
We report the case of a patient who developed extensive brain lesions during fingolimod (FTY720) treatment in the TRANSFORMS study. His initial diagnosis was multiple sclerosis, but after encephalopathy anti-aquaporin4 antibody (anti-AQP4 Ab) was detected, it was changed to neuromyelitis optica spectrum disorder. After treatment with fingolimod, he developed bilateral extensive brain lesions. The brain MRI showed lesions predominantly involving the right frontal and parietal lobes, with vasogenic edema and enhancement. He had residual encephalomalacia and no recurrence with steroid treatment over 3 years following withdrawal of fingolimod.Keywords
This publication has 6 references indexed in Scilit:
- IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrumNeurology, 2010
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- “Cloud‐like enhancement” is a magnetic resonance imaging abnormality specific to neuromyelitis opticaAnnals of Neurology, 2009
- Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disordersNeurology, 2009
- Aquaporin-4 Antibodies in Neuromyelitis Optica and Longitudinally Extensive Transverse MyelitisArchives of Neurology, 2008
- Acute Disseminating Encephalomyelitis in Neuromyelitis OpticaArchives of Neurology, 2008